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Notre-Dame, Montre´al, Que´bec, CanadaOSTEOARTHRITIS (OA) is characterized by the progres-
sive erosion of the articular cartilage as well as
subchondral bone remodeling, which leads to an
increase in bone density that may possibly cause
cartilage damage. In a study, we examined in vivo
the e#ect of the nonsteroidal antiinflammatory
drug (NSAID), carprofen, on the structural
changes of the experimental dog model of OA.
The e#ect of the drug on the metabolism of
subchondral bone cells was also studied.
A total of three groups of dogs were included in
this study. Group I received a sectioning of the
anterior cruciate ligament and was administered
carprofen (2.2 mg/kg/bid/po) for eight weeks begin-
ning four weeks post surgery. Groups II and III
were operated on and received no treatment. The
dogs in groups I and II were killed 12 weeks after
surgery, while the dogs in group III were killed
four weeks post surgery. Normal dogs were used as
control.
The dogs were killed via intravenous injection
of an euthanasic substance (t-61). The proximal
end of the tibia and the distal end of the femur
were removed and placed on ice prior to and
throughout dissection. Cartilage lesions were
assessed according to size (mm2) and grade (scale
0–4) as previously described [1]. Samples from
the lesion areas of the condyles and plateaus
were fixed in bu#ered 10% formalin, embedded in
paraffin, and stained with hematoxylin eosin or
safranin-0. The severity of lesions was graded
according to the Mankin scale (grade 0–14) [2].
Primary osteoblast-like cell cultures were pre-
pared from explants of tibial plateau subchondral
bone plates removed from the right knees of the
dogs [3]. Normal dog primary osteoblast cell cul-
tures were also prepared in parallel using tibial
subchondral bone explant specimens.
There was a tendency for the grade of lesions to
be lower in dogs treated with carprofen as com-327pared with the 12-week OA group. For the femoral
condyles, the severity of lesions in the carprofen
group was not significantly di#erent when com-
pared with the lesions in the 12-week OA group.
For the tibial plateaus, the severity of lesions
in the carprofen-treated group (3.7&0.6;
mean&standard error) was significantly less
(P<0.04) than that found in the 12-week OA group
(6.1&0.6).
All primary dog osteoblast cell cultures showed
osteoblast-like features, namely high alkaline
phosphatase activity and osteocalcin release [3].
Our 12-week OA group showed an increased vita-
min D (1,25(OH)2D3)-induced alkaline phosphatase
activity as compared with the cells obtained from
our normal group. Cells from the carprofen group
showed results similar to the normal group. Like-
wise, basal alkaline phosphatase activity followed
a similar trend, however failed to reach signifi-
cance between groups. Osteocalcin secretion by
these osteoblast-like cells was increased several-
fold in response to 1,25(OH)2D3 treatment, a good
indication that these cells are indeed functional
osteoblasts. Basal and 1,25(OH)2D3-induced osteo-
calcin release by the 12-week OA group was
increased compared with both normal and carpro-
fen groups; this di#erence reached significance
only under basal conditions. Hence, 1,25(OH)2D3-
induction was partially impaired in OA cells as
compared with the two other groups. Urokinase
plasminogen activator activity was also reduced
by carprofen treatment as compared with the OA
group, under both basal and insulin-like growth
factor-1 (IGF-1) stimulation. Lastly, IGF-1 produc-
tion by OA osteoblast-like cells was reduced in
response to carprofen treatment.
This study has shown that, in the experimental
dog model of OA, under therapeutic conditions,
treatment with carprofen can reduce the severity
of cartilage lesions. These results also indicate
328 Pelletier et al.: Carprofen in experimental osteoarthritisthat functional osteoblast-like cells can be
obtained from dog tibial subchondral bone. They
also suggest that osteoblasts from this animal
model of OA have abnormal in-vitro behavior as
compared to normal animals, and that carprofen
treatment can prevent these e#ects. Hence, this
indicates that carprofen can retard and/or prevent
the abnormal metabolism of subchondral osteo-
blasts in this OA model. Whether this e#ect is
linked to the structurally protective e#ect of
carprofen remains to be determined.References
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